Responsiveness to change in health-related quality of life in a randomized clinical trial: A comparison of the prostate cancer specific quality of life instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module

Journal of Clinical Epidemiology

Volumn 51, Issue 2, 1998, Pages 137-145

  Stockler, Martin R ^a,b   Osoba, David ^c   Goodwin, Pamela ^d,e   Corey, Paul ^d   Tannock, Ian F ^a,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Prostatic neoplasms; Psychometrics; Quality of life; Questionnaires; Randomized controlled trial; Reproducibility; Self assessment (psychology)

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EMOTIONALITY; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PAIN ASSESSMENT; PALLIATIVE THERAPY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REPRODUCIBILITY; SOCIAL STATUS; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PALLIATIVE CARE; PREDNISONE; PROSTATIC NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0031886726     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(97)00269-2     Document Type: Article

References (30)

1. Kirshner B, Guyatt GH A methodologic framework for assessing health indices. J Chronic Dis. 38:1985;27-36.
2. Feinstein AR Clinimetrics. 1987;Yale University Press, New Haven, CT.
3. Tannock IF, Osoba D, Stockler MRet al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer. A Canadian randomized trial with palliative end points J Clin Oncol. 14:1996;1756-1764.
4. Tannock I, Gospodarowicz M, Meakin Wet al. Treatment of metastatic prostate cancer with low dose prednisone. Evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol. 7:1989;590-597.
5. Melzack R The McGill pain questionnaire. Major properties and scoring methods Pain. 1:1975;277-299.
6. Melzack R The short form McGill Pain Questionnaire. Pain. 30:1987;191-197.
7. Aaronson NK, Ahmedzai S, Bergman Bet al. The European Organisation for Research and Treatment of Cancer QLQ-C30. A quality of life instrument for use in international clinical trials in oncology J Natl Cancer Inst. 85:1993;365-376.
8. Aaronson NK, Bullinger M, Ahmedzai S A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res. 111:1988;231-249.
9. Sprangers MAG, Cull A, Bjordal K, Groenvold M The European Organization for Research and Treatment of Cancer approach to quality of life assessment. Guidelines for developing questionnaire modules Quality Life Res. 2:1993;287-295. Aaranoson NK for the EORTC Study Group on Quality of Life.
10. Lehmann EL Non-Parametrics. Statistical Methods Based on Ranks:1975;Holden-Day, San Fransisco, CA.
11. Armitage P, Berry G Statistical Methods in Medical Research. 2:1987;Blackwell Scientific Publications, Oxford. 419.
12. Effron B, Tibshirani RJ An Introduction to the Bootstrap. 1993;Chapman and Hall, New York.
13. Moore MJ, Osoba D, Murphy Ket al. The use of palliative endpoints to evaluate the effects of mitoxantrone and low dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 12:1994;689-694.
14. Stockler M. Validation of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) as an outcome measure for clinical trials in advanced hormone-resistant prostate cancer; assessment of convergent, discriminative, and predictive validity with baseline data from a randomised trial. (thesis) Toronto, ON: University of Toronto; 1996.
15. Ringdal GI, Ringdal K Testing the EORTC quality of life questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res. 2:1993;129-140.
16. Niezogoda HE, Pater JL A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res. 2:1993;319-325.
17. Osoba D, Zee B, Pater Jet al. Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian, and lung cancer. Qual Life Res. 3:1994;353-364.
18. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S Test/retest study of the European Organisation for Research and Treatment of Cancer core quality of life questionnaire. J Clin Oncol. 13:1995;1249-1254.
19. Osoba D, Pater JL, Zee Bet al. Effective anti-emetic therapy improves quality of life (QOL) after moderately emetogenic chemotherapy (MEC). Qual Life Res. 4:1995;467. Abstract.
20. Zubrod CG, Schneiderman M, Frei Eet al. Appraisal of methods for the study of chemotherapy of cancer in man. comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide J Chron Dis. 11:1960;7-33.
21. Osoba D, Aaronson NK, Muller Met al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol. 34:1997;263-278.
22. Osoba D, Rodrigues G, Myles J, Pater J Significance of changes in health-related quality of life (QOL) scores in women receiving chemotherapy for recurrent or metastatic breast cancer. Qual Life Res. 4:1995;467. Abstract.
23. Bombardier C, Raboud J, Auranofin Cooperating Group A comparison of health-related quality of life measures for rheaumatoid arthritis research. Controlled Clin Trials. 12:1991;243S-256S.
24. Kazis LE, Anderson JJ, Meenan RF Effect sizes for interpreting changes in health status. Med Care. 27:1989;S178-S189.
25. Beaton DE, Hogg-Johnson S, Bombardier C Evaluating changes in health status. Reliability and responsiveness of five generic health status measures in the soft tissue injuries J Clin Epidemiol. 50:1997;79-93.
26. Gliklich RE, Hilinski JM Longitudinal sensitivity of generic and specific health measures in chronic sinusitis. Qual Life Res. 4:1995;27-32.
27. Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH Comparative measurement sensitivity of short and longer health status instruments. Med Care. 30:1992;917-925.
28. Liang MH, Fossel AH, Larson MG Comparisons of five health status instruments for orthopedic evaluation. Med Care. 28:1990;632-642.
29. Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A Responsiveness and validity in health status measurement. a clarification J Clin Epidemiol. 42:1989;403-408.
30. Hays RD, Hadorn D Responsiveness to change. an aspect of validity, not a separate dimension Qual Life Res. 1:1992;73-75.